In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Threshold out-licenses TH302 to Merck Serono; Phase III trials fail and deal ends

Executive Summary

Threshold Pharmaceuticals Inc. (cancer drug development) has granted Merck KGAA’s Merck Serono SA division rights to co-develop and exclusively sell globally its TH302, a hypoxia-targeted compound in Phase III trials for soft tissue sarcoma, and in additional studies for other cancers. Threshold retains an option to co-promote in the US, giving it the chance to receive 50% of the profits in that territory.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies